<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02993367</url>
  </required_header>
  <id_info>
    <org_study_id>ZYF55688</org_study_id>
    <nct_id>NCT02993367</nct_id>
  </id_info>
  <brief_title>The Efficacy of Butylphthalide Soft Capsules in Patents With VCIND</brief_title>
  <acronym>EBSCPVCIND</acronym>
  <official_title>The Efficacy of Butylphthalide Soft Capsules in Patents With VCIND:A Randomized, Double-blind,and Neuroimaging Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The Second Hospital of Hebei Medical University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>The Second Hospital of Hebei Medical University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Vascular cognitive impairment no dementia (VCIND) is very common among the aged and tends to
      progress to dementia, but there have been no proper large-scale intervention trials dedicated
      to it. VCIND caused by subcortical ischemic small vessel disease (hereinafter, subcortical
      VCIND) represents a relatively homogeneous disease process and is a suitable target for
      therapeutic trials investigating VCIND. Preclinical trials showed that Butylphthalide Soft
      Capsules is effective for cognitive impairment of vascular origin. In this randomized,
      double-blind, placebo-controlled trial, the investigators apply fMRI study the effects of
      Butylphthalide Soft Capsules in patients with VCIND.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 2017</start_date>
  <completion_date type="Anticipated">July 2019</completion_date>
  <primary_completion_date type="Anticipated">January 2019</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>change of Cognitive function</measure>
    <time_frame>Time points 0, 1, 3 and 6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>change of brain function</measure>
    <time_frame>Time point at 0, 1, 3, 6 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Vascular Cognitive Impairment no Dementia</condition>
  <arm_group>
    <arm_group_label>the Butylphthalide Soft Capsules group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>600mg Butylphthalide Soft Capsules/day,po tid,period of 6 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>the placebo group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>60mg Butylphthalide Soft Capsules/day,po tid,period of 6 months</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Butylphthalide Soft Capsules</intervention_name>
    <description>DL-3-n-butylphthalide (NBP) (Fig. 1) is a synthetic chiral compound containing L- and D-isomers of butylphthalide.Butylphthalide Soft Capsules is the oral preparation.</description>
    <arm_group_label>the Butylphthalide Soft Capsules group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo Butylphthalide Soft Capsules</intervention_name>
    <arm_group_label>the placebo group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Literate Han Chinese aged from 40 to 65 years

          -  MMSE â‰¥24

          -  Normal or slightly impaired activities of daily living

          -  The MRI entry criteria are as follows:

               -  Subcortical small infarcts (3-20 mm in diameter),or one or more strategically
                  located subcortical small infarcts in the caudate nucleus globus pallidus, or
                  thalamus

               -  Absence of cortical and watershed infarcts, hemorrhages, hydrocephalus, and WMLs
                  with specific causes (e.g., multiple sclerosis); and

               -  No hippocampal or entorhinal cortex atrophy (scored 0 according to medial
                  temporal lobe atrophy scale of Scheltens)

        Exclusion Criteria:

          -  Patients with Diabetes mellitus

          -  Disorders other than subcortical VCIND that may affect cognition; the score of
             Hamilton depression scale more than 17 or schizophrenia

          -  Clinically significant gastrointestinal, renal, hepatic, respiratory, infectious,
             endocrine, or cardiovascular system disease; cancer; alcoholism; drug addiction; use
             of medications that may affect cognitive functioning

          -  Known hypersensitivity to celery

          -  Inability to undergo a brain MRI
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yifei Zhu, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Second Hospital of Hebei Medical University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Yifei Zhu, M.D.</last_name>
    <phone>+8613303046666</phone>
    <email>13831155688@163.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Panpan Liang, M.D.</last_name>
    <phone>+8617717711528</phone>
    <email>2354672781@qq.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Second Affiliated Hospital of Hebei medical university</name>
      <address>
        <city>Shijiazhuang</city>
        <state>Hebei</state>
        <zip>050000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>zhu yifei, master</last_name>
      <phone>+8613303046666</phone>
      <email>13831155688@163.com</email>
    </contact>
    <contact_backup>
      <last_name>liang panpan, master</last_name>
      <phone>+8617717711528</phone>
      <email>674691785@qq.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <results_reference>
    <citation>Jia J, Wei C, Liang J, Zhou A, Zuo X, Song H, Wu L, Chen X, Chen S, Zhang J, Wu J, Wang K, Chu L, Peng D, Lv P, Guo H, Niu X, Chen Y, Dong W, Han X, Fang B, Peng M, Li D, Jia Q, Huang L. The effects of DL-3-n-butylphthalide in patients with vascular cognitive impairment without dementia caused by subcortical ischemic small vessel disease: A multicentre, randomized, double-blind, placebo-controlled trial. Alzheimers Dement. 2016 Feb;12(2):89-99. doi: 10.1016/j.jalz.2015.04.010. Epub 2015 Jun 15.</citation>
    <PMID>26086183</PMID>
  </results_reference>
  <verification_date>March 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 8, 2016</study_first_submitted>
  <study_first_submitted_qc>December 12, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 15, 2016</study_first_posted>
  <last_update_submitted>March 15, 2017</last_update_submitted>
  <last_update_submitted_qc>March 15, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 16, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>The Second Hospital of Hebei Medical University</investigator_affiliation>
    <investigator_full_name>Yifei Zhu</investigator_full_name>
    <investigator_title>Clinical Professor</investigator_title>
  </responsible_party>
  <keyword>Butylphthalide Soft Capsules</keyword>
  <keyword>VCIND</keyword>
  <keyword>fMRI</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dementia</mesh_term>
    <mesh_term>Cognitive Dysfunction</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>3-n-butylphthalide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

